Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes

Thrombosis and Haemostasis

Volumn 79, Issue 1, 1998, Pages 110-118

  Gustafsson, D ^a   Antonsson, T ^a   Bylund, R ^a   Eriksson, U ^a   Gyzander, E ^a   Nilsson, I ^a   Elg, M ^a   Mattsson, C ^a   Deinum, J ^a   Pehrsson, S ^a   Karlsson, O ^a   Nilsson, A ^a   Sorensen H ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INOGATRAN; MELAGATRAN; PLASMIN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; FIBRINOLYSIS; HUMAN; HUMAN CELL; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION;

EID: 0031984477     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614245     Document Type: Article

References (31)

1. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-9.
2. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
3. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and thrombin Inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.
4. Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991; 9: 247-63.
5. Kimball SD. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul Fibrinol 1995; 6: 511-9.
6. Antonsson KT, Bylund R, Gustafsson ND, Nilsson IO. Trypsin-like protease-inhibiting peptide derivatives, their synthesis and therapeutic use. Patent application W09429336-A1. CA122-285553/23.
7. Teger-Nilsson AC, Bylund R. Preparation of peptide derivatives as thrombin inhibitors. Patent application W09311152-A1. CA121-083990/07.
8. Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-97.
9. Åstedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroentol Suppl 1987; 137: 22-5.
10. Kluft C. Occurrence of C1 inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemost 1976; 5: 136-46.
11. Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, Mineo K, Okamoto S. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Haemost 1986; 56: 28-34.
12. Lenfors S, Gustafsson D. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: Effects of thrombin inhibitors. Semin Thromb Haemost 1996; 22: 335-42.
13. Nilsson T, Sjöling-Ericksson Å, Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human α-thrombin. J Enzym Inhib 1997; accepted.
14. Bajusz S, Szell E, Bagdy D, Barabas E, Horvath G, Dioszegi M, Fittler Z, Szabo G, Juhasz A, Tomori E, Szilagyi G. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Medicinal Chem 1990; 33: 1729-35.
15. Cousins GR, Friedrichs GS, Sudo Y, Rebello SS, Rote WE, Vlasuk GP, Nolan TG, Mendoza C, Lucchesi BR. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. Circulation 1996; 94: 1705-12.
16. EIg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92.
17. Kessels H, Willems G, Hemker C. Analysis of thrombin generation in plasma. Comput Biol Med 1994; 24: 277-88.
18. Teger-Nilsson AC, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective LMW thrombin Inhibitor. Thromb Res 1997; 85:133-45.
19. Bridey F, Dreyfus M, Parent F, Bros A, Fischer AM, Camez A, Simonneau G, Duroux P, Meyer D. Recombinant hirudin (HBW 023): Biological data often patients with severe venous thromboembolism. Am J Hematol 1995; 49: 67-72.
20. Hauptmann J, Markwardt F. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Semin Thromb Hemost 1992; 18: 200-17.
21. Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 1992; 18: 135-49.
22. Mattson C, Eriksson E, Nilsson S. Anticoagulant and antithrombotic ettects of some protease inhibitors. Folia Haematol (Leipzig) 1982; 109: S 43-51.
23. Metha JL, Chen L, Mattsson C, Gustafsson D, Saldeen TGP. Melagatran, an oral active site inhibitor of thrombin, prevents or delays formation of electrically-induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol, accepted.
24. Pharmacokinetics of inogatran, a new low molecular weight thrombin inhibitor, in rats and dogs. Eriksson UG, Renberg L, Vedin C, Strimfors M. Thromb Haemost 1995; 73: 1318 (Abstract 1605).
25. Bagdy D. Szabó G, Barabás É, Bajusz S. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. Thromb Haemost 1992; 68: 125-9.
26. Hussain MA, Knabb R, Aungst BJ, Kettner C. Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration. Peptides 1991; 12: 1153-4.
27. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
28. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
29. Carr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma dots. Blood Coagul Fibrinol 1995; 6: 567-73.
30. Mattsson C, Björkman JA, Ulvinge JC. Hirudin and melagatran, a reversible, low molecular weight thrombin inhibitor, as adjunctive agents to tissue type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinol Proteol 1997; 11: 121-8.
31. Kopéc M, Latallo ZS, Stahl M, Wegrzynowicz. The effects of proteolytic enzymes on fibrin stabilizing factor. Biochem Biophys Acta 1969; 181: 437-45.